to discuss whether or not to recommend approving EnteroMedics ' ( ETRM ) Maestro System therapy for treating morbid obesity ..... will take place on June 17 rather than on May 29. EnteroMedics said the delay is due to a scheduling conflict
Gainers: LCAV +27% . LOGM +20% . JCOM +13% . LIVE +11% . SYMX +11% . ETRM +8% . MHR +7% . CLF +7% . ACO +7% . CIEN +6% . BRD +5% . PQ +5% . Losers: WTW -22% . SVM -15% . TRLA -15
Gainers: ACO +12% . ETRM +13% . OC +10% . VICL +10% . STV +10% . CYNO +8% . DVA +7% . LIVE +7% . PKG +6% . OPTT +5% . Losers: VTUS -64% . OXGN -24% . RLOC -17% . PRGN -12% . FEYE -5% . Post your comment!
EnteroMedics ( ETRM ): Q4 EPS of -$0.11 misses by $0.01 . Press Release Post your comment!
We are no longer providing equity research on EnteroMedics ETRM . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
will be a significant obstacle for EnteroMedics . With limited reimbursement, Maestro ..... neurostimulation that leads to weight loss. EnteroMedics ' key patent that covers electrical ..... million-16 million patients available to EnteroMedics .Even though Maestro's effectiveness
EnteroMedics ETRM posted third-quarter results that ..... value estimate unchanged. Although EnteroMedics has begun to roll out its Maestro system ..... until after 2017. In the meantime, EnteroMedics burned through another $5.6 million
EntroMedics ETRM has made significant progress ..... valuation shortly. Now that EnteroMedics has shored up its cash ..... full year 2012. While EnteroMedics began its launch in Kuwait ..... 2013, especially after EnteroMedics has submitted its last
Now that EnteroMedics ETRM has made significant progress on ..... Australia. For the first time, EnteroMedics booked product revenue, following ..... distributor. Perhaps most important, EnteroMedics has put financing in place to keep
EnteroMedics ETRM saw its shares run up substantially ..... outcome has breathed some hope into EnteroMedics ' stock. However, this is not enough ..... to raise our fair value estimate for EnteroMedics at this time. Nonetheless, we are